查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1387432

血友病治療市場報告：2030 年趨勢、預測與競爭分析

Hemophilia Treatment Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

血友病治療的趨勢與預測

預計到 2030 年，全球血友病治療市場將達到約 184 億美元，2024 年至 2030 年年複合成長率為 5.2%。市場的主要促進因素是大量的血友病患者、血友病預防性治療的可用性以及有利的政府配合措施。全球血友病治療市場的未來看起來充滿希望，A型血友病 A和B型血友病市場充滿機會。

血友病治療市場洞察

Lucintel 預測，由於可用的重組產品數量眾多，重組凝血因子濃縮物預計在預測期內仍將是最大的細分市場。

由於血友病患者數量不斷增加以及對先進技術產品的認知不斷增強，預計歐洲在預測期內仍將是最大的地區。

本報告回答了 11 個關鍵問題：

  • Q.1. 細分市場中最有前途和高成長的機會是什麼？
  • Q.2.哪個細分市場將以更快的速度成長？為什麼？
  • Q.3.您認為哪些地區未來會出現更快的成長？為什麼？
  • Q.4. 影響市場動態的主要因素有哪些？市場的主要挑戰和商業風險是什麼？
  • Q.5. 這個市場的商業風險和競爭威脅是什麼？
  • Q.6.這個市場有哪些新趨勢？為什麼？
  • Q.7.市場客戶需求有何改變？
  • Q.8. 該市場有哪些新發展以及哪些公司處於領先地位？
  • Q.9.這個市場的主要企業有哪些？主要企業採取哪些策略配合措施來發展業務？
  • Q.10. 該市場上的競爭產品有哪些？由於材料或產品替代而導致市場佔有率下降的威脅有多大？
  • Q.11.過去年度發生了哪些併購事件，對產業產生了哪些影響？

目錄

第1章 執行摘要

第2章 全球血友病治療市場：市場動態

  • 簡介、背景、分類
  • 供應鏈
  • 產業促進因素與挑戰

第3章 2018-2030年市場趨勢及預測分析

  • 宏觀經濟趨勢（2018-2023）與預測（2024-2030）
  • 全球血友病治療市場趨勢（2018-2023）與預測（2024-2030）
  • 按類型分類的全球血友病治療市場
    • A型血友病
    • B型血友病
  • 全球血友病藥物治療市場
    • 重組凝血因子濃縮物
    • 血漿衍生凝血因子濃縮物
    • 非因子替代療法
  • 按最終用途分類的全球血友病治療市場
    • 醫院
    • 診所
    • 其他

第4章 2018-2030年分地區市場趨勢及預測分析

  • 全球血友病治療市場（按地區）
  • 北美血友病治療市場
  • 歐洲血友病治療市場
  • 亞太地區血友病治療市場
  • 其他地區血友病治療市場

第5章 競爭分析

  • 產品系列分析
  • 營運整合
  • 波特五力分析

第6章 成長機會與策略分析

  • 成長機會分析
    • 按類型分類的全球血友病治療市場成長機會
    • 藥物治療的全球血友病治療市場成長機會
    • 全球血友病治療市場成長機會（依最終用途）
    • 按地區分類的全球血友病治療市場成長機會
  • 全球血友病治療市場的新興趨勢
  • 戰略分析
    • 新產品開發
    • 擴大全球血友病治療市場的產能
    • 全球血友病治療市場的合併、收購與合資企業
    • 認證和許可

第7章 主要企業概況

  • Baxter
  • Octapharma
  • CSL Limited
  • Grifols
  • Bayer
  • Pfizer
  • Sanofi
  • Ferring
  • BioMarin
  • Sangamo Therapeutics
簡介目錄

Hemophilia Treatment Trends and Forecast

The future of the global hemophilia treatment market looks promising with opportunities in the hemophilia A and hemophilia B markets. The global hemophilia treatment market is expected to reach an estimated $18.4 billion by 2030 with a CAGR of 5.2% from 2024 to 2030. The major drivers for this market are large numbers of hemophilia patients, usage of prophylactic treatment for hemophilia, and favorable government initiatives.

A more than 150-page report is developed to help in your business decisions.

Hemophilia Treatment by Segment

The study includes a forecast for the global hemophilia treatment by type, drug therapy, end use, and region.

Hemophilia Treatment Market by Type [Shipment Analysis by Value from 2018 to 2030]:

  • Hemophilia A
  • Hemophilia B

Hemophilia Treatment Market by Drug Therapy [Shipment Analysis by Value from 2018 to 2030]:

  • Recombinant Coagulation Factor Concentrates Therapy
  • Plasma Derived Coagulation Factor Concentrates Therapy
  • Non-Factor Replacement Therapy

Hemophilia Treatment Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Hospitals
  • Clinics
  • Others

Hemophilia Treatment Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Hemophilia Treatment Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies hemophilia treatment companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the hemophilia treatment companies profiled in this report include-

  • Baxter
  • Octapharma
  • CSL Limited
  • Grifols
  • Bayer
  • Pfizer
  • Sanofi
  • Ferring
  • BioMarin
  • Sangamo Therapeutics

Hemophilia Treatment Market Insights

Lucintel forecasts that recombinant coagulation factor concentrates therapy will remain the largest segment over the forecast period because of the large number of recombinant technology products available for the treatment.

Europe will remain the largest region over the forecast period due to increasing number of hemophilic patients and rising awareness about technologically advanced products in the region.

Features of the Global Hemophilia Treatment Market

Market Size Estimates: Hemophilia treatment market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Hemophilia treatment market size by type, drug therapy, end use, and region in terms of value ($B).

Regional Analysis: Hemophilia treatment market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different type, drug therapy, end use, and regions for the hemophilia treatment market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the hemophilia treatment market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the hemophilia treatment market size?

Answer: The global hemophilia treatment market is expected to reach an estimated $18.4 billion by 2030.

Q2. What is the growth forecast for hemophilia treatment market?

Answer: The global hemophilia treatment market is expected to grow with a CAGR of 5.2% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the hemophilia treatment market?

Answer: The major drivers for this market are large numbers of hemophilia patients, usage of prophylactic treatment for hemophilia, and favorable government initiatives.

Q4. What are the major segments for hemophilia treatment market?

Answer: The future of the global hemophilia treatment market looks promising with opportunities in the hemophilia A and hemophilia B markets.

Q5. Who are the key hemophilia treatment market companies?

Answer: Some of the key hemophilia treatment companies are as follows:

  • Baxter
  • Octapharma
  • CSL Limited
  • Grifols
  • Bayer
  • Pfizer
  • Sanofi
  • Ferring
  • BioMarin
  • Sangamo Therapeutics

Q6. Which hemophilia treatment market segment will be the largest in future?

Answer: Lucintel forecasts that recombinant coagulation factor concentrates therapy will remain the largest segment over the forecast period because of the large number of recombinant technology products available for the treatment.

Q7. In hemophilia treatment market, which region is expected to be the largest in next 5 years?

Answer: Europe will remain the largest region over the forecast period due to increasing number of hemophilic patients and rising awareness about technologically advanced products in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the hemophilia treatment market by type (hemophilia A and hemophilia B), drug therapy (recombinant coagulation factor concentrates therapy, plasma derived coagulation factor concentrates therapy, and non-factor replacement therapy), end use (hospitals, clinics, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Hemophilia Treatment Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Hemophilia Treatment Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Hemophilia Treatment Market by Type
    • 3.3.1: Hemophilia A
    • 3.3.2: Hemophilia B
  • 3.4: Global Hemophilia Treatment Market by Drug Therapy
    • 3.4.1: Recombinant Coagulation Factor Concentrates Therapy
    • 3.4.2: Plasma Derived Coagulation Factor Concentrates Therapy
    • 3.4.3: Non-Factor Replacement Therapy
  • 3.5: Global Hemophilia Treatment Market by End Use
    • 3.5.1: Hospitals
    • 3.5.2: Clinics
    • 3.5.3: others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Hemophilia Treatment Market by Region
  • 4.2: North American Hemophilia Treatment Market
    • 4.2.2: North American Hemophilia Treatment Market by Drug Therapy: Recombinant Coagulation Factor Concentrates Therapy, Plasma Derived Coagulation Factor Concentrates Therapy, and Non-Factor Replacement Therapy
  • 4.3: European Hemophilia Treatment Market
    • 4.3.1: European Hemophilia Treatment Market by Type: Hemophilia A and Hemophilia B
    • 4.3.2: European Hemophilia Treatment Market by Drug Therapy: Recombinant Coagulation Factor Concentrates Therapy, Plasma Derived Coagulation Factor Concentrates Therapy, and Non-Factor Replacement Therapy
  • 4.4: APAC Hemophilia Treatment Market
    • 4.4.1: APAC Hemophilia Treatment Market by Type: Hemophilia A and Hemophilia B
    • 4.4.2: APAC Hemophilia Treatment Market by Drug Therapy: Recombinant Coagulation Factor Concentrates Therapy, Plasma Derived Coagulation Factor Concentrates Therapy, and Non-Factor Replacement Therapy
  • 4.5: ROW Hemophilia Treatment Market
    • 4.5.1: ROW Hemophilia Treatment Market by Type: Hemophilia A and Hemophilia B
    • 4.5.2: ROW Hemophilia Treatment Market by Drug Therapy: Recombinant Coagulation Factor Concentrates Therapy, Plasma Derived Coagulation Factor Concentrates Therapy, and Non-Factor Replacement Therapy

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Hemophilia Treatment Market by Type
    • 6.1.2: Growth Opportunities for the Global Hemophilia Treatment Market by Drug Therapy
    • 6.1.3: Growth Opportunities for the Global Hemophilia Treatment Market by End Use
    • 6.1.4: Growth Opportunities for the Global Hemophilia Treatment Market by Region
  • 6.2: Emerging Trends in the Global Hemophilia Treatment Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Hemophilia Treatment Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Hemophilia Treatment Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Baxter
  • 7.2: Octapharma
  • 7.3: CSL Limited
  • 7.4: Grifols
  • 7.5: Bayer
  • 7.6: Pfizer
  • 7.7: Sanofi
  • 7.8: Ferring
  • 7.9: BioMarin
  • 7.10: Sangamo Therapeutics